Metabolon and Colgate Identify Early Biomarkers in Periodontal Disease
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Metabolon, Inc., announces the publication of “Assessment of Dentifrice on Periodontal Disease Biomarkers in Gingival Crevicular Fluid”, in the Journal of Periodontology.
The article reports the results of a biomarker validation study carried out in collaboration with co-authors Virginia M. Barnes and colleagues of Colgate-Palmolive.
Periodontal disease, described as inflammation of the gums, is among the most common infectious diseases. Triclosan, the active ingredient in Colgate Total (CT), is a proven therapeutic agent against gingivitis. CT is the only FDA approved dentifrice for the treatment of gingivitis.
The study follows previous research by Dr. Barnes and collaborators at Colgate-Palmolive Company which used Metabolon’s patented global metabolomic profiling platform to identify candidate biomarkers in gingival crevicular fluid samples from subjects with chronic periodontitis.
In this latest report, the biomarkers associated with gingivitis and periodontitis identified in the previous study, were validated as sensitive indicators for periodontal diseases. The levels of inosine, lysine, putrescine and xanthine correlated with the therapeutic effects of brushing with CT, a triclosan-containing dentrifice, against gingivitis and provided biochemical confirmation that CT can provide therapeutic improvement against gingivitis. These four biomarkers were significantly altered before observable clinical changes suggesting they could be useful for rapidly assessing clinical efficacy of anti-gingivitis products.
The article reports the results of a biomarker validation study carried out in collaboration with co-authors Virginia M. Barnes and colleagues of Colgate-Palmolive.
Periodontal disease, described as inflammation of the gums, is among the most common infectious diseases. Triclosan, the active ingredient in Colgate Total (CT), is a proven therapeutic agent against gingivitis. CT is the only FDA approved dentifrice for the treatment of gingivitis.
The study follows previous research by Dr. Barnes and collaborators at Colgate-Palmolive Company which used Metabolon’s patented global metabolomic profiling platform to identify candidate biomarkers in gingival crevicular fluid samples from subjects with chronic periodontitis.
In this latest report, the biomarkers associated with gingivitis and periodontitis identified in the previous study, were validated as sensitive indicators for periodontal diseases. The levels of inosine, lysine, putrescine and xanthine correlated with the therapeutic effects of brushing with CT, a triclosan-containing dentrifice, against gingivitis and provided biochemical confirmation that CT can provide therapeutic improvement against gingivitis. These four biomarkers were significantly altered before observable clinical changes suggesting they could be useful for rapidly assessing clinical efficacy of anti-gingivitis products.
